Travere Therapeutics
TVTX
65 hedge funds and large institutions have $266M invested in Travere Therapeutics in 2014 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 7 closing their positions.
7,292% more call options, than puts
Call options by funds: $3.55M | Put options by funds: $48K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
88% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 16
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
61% more capital invested
Capital invested by funds: $165M → $266M (+$101M)
8% more funds holding
Funds holding: 60 → 65 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$10.5M |
| 2 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$8.8M |
| 3 |
PA
Perceptive Advisors
New York
|
+$5.81M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.09M |
| 5 |
SAM
Senzar Asset Management
New York
|
+$3.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
-$10.9M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
-$2.62M |
| 3 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$1.16M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$917K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$828K |
TVTX Hedge Fund Activity: Q4 2014 in Review
65 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q4 2014, worth a combined $266M — up 61% from $165M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TVTX positions and 7 closed out — a net gain of 6 holders — while 30 added to existing stakes and 16 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $10.5M. The largest seller was QVT Financial, cutting an estimated $10.9M.
- 65 institutional investors held Travere Therapeutics (TVTX) as of Q4 2014, up from 60 in Q3 2014.
- Funds reported $266M of Travere Therapeutics stock for Q4 2014, up 61% quarter-over-quarter.
- 13 funds opened new Travere Therapeutics positions in Q4 2014 and 7 closed out, a net change of +6 holders.
- The largest Travere Therapeutics buyer in Q4 2014 was Consonance Capital Management, an estimated $10.5M added.
- The largest Travere Therapeutics seller in Q4 2014 was QVT Financial, an estimated $10.9M sold.
Based on aggregated 13F filings for Q4 2014.